Статья
ЭНДОТЕЛИАЛЬНАЯ ДИСФУНКЦИЯ И ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ
Эндотелиальная дисфункция и острый коронарный синдром.
1. Афанасьев И.Б. Свободно-радикальные ингибиторы и промоторы в биологических процессах. – В кн.: Кислородные радикалы в химии, биологии и медицине, Рига, 1988. - С.9-25.
2. Грацианский Н.А. Нестабильная стенокардия – острый коронарный синдром. Некоторые новые факты о патогенезе и их значение для лечения // Кардиология.- 1996.-N.11.- C.4-15.
3. Денисенко А.Д., Виноградов А.Г., Пивоварова Ю.И. с соавт. Влияние блокады ретикулоэндотелиальной системы на метаболизм липопротеидов низкой плотности //Вопр. мед. химии.- 1993.-Т.39.-N.3.-С.6-8.
4. Жданов В.С. Некоторые актуальные вопросы патологической анатомии коронарного атеросклероза //Арх. патол.-1993.-N.2.-С.39-45.
5. Зильбер А.П. Медицина критических состояний. Общие проблемы.- Петрозаводск, 1995.-Т.1.- 357с.
6. Климов А.Н., Никульчева Н.Г. Обмен липидов и липопротеидов и его нарушения - Санкт-Петербург, 1999.-512с.
7. Куимов А.Д., Маянская С.Д., Барбарич В.Б. Антиоксидантная активность триметазидина в лечении острого инфаркта миокарда // Рос. кард. журнал, Мат. VI Всеросийского съезда кардиологов.- Москва.-1999.-N 4 (приложение).-С.83-84.
8. Маянский Д.Н., Маянская С.Д. Лейкоцитарные механизмы острого коронарного синдрома //Бюл.СОРАМН.-1998.-N.2.-С.41-45.
9. Маянский Д.Н., Урсов И.Г. Лекции по клинической патологии.-Новосибирск, 1997.- 249с.
10. Маянская С.Д. Воспалительные реакции при ишемической болезни сердца и подходы к их коррекции // Автореф. докт. дис., 1999.
11. Маянская С.Д., Маянская Н.Н., Куимов А.Д., Цырендоржиев Д.Д., Ефремов А.В. Функциональная активность лейкоцитов крови у больных нестабильной стенокардией и острым инфарктом миокарда. Перспективы исследования //Рос. кард. журнал.-1999.-N.5.- С.15-17.
12. РуксинВ. В. Тромбозы в кардиологической практике. – Санкт - Петербург, 1998. -126с.
13. Anker S.D., Ponikowski P.P., Clark A.L. et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure // Eur.Heart J.-1999.- V.20.-N.9.-p.683-694.
14. Aversano T., Zhou W., Nedelman M. et al. A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion // J.Amm.Coll.Cardiol.-1995.-V.25.-p.781-7881.
15. Berk B.C. Weintraub W,S., Alexander R.W. Elevation of C-reactive protein in «active» coronary artery disease //Am. J.Cardiol.-1990.- N.65.-p.168-172.
16. Bevilacqua M.P., Pober J., Mendrick D. et al. Identification of an inducible endothelial-leukocyte adhesion molecule //Proc. Natl, Acad. Sci. USA. -1987.-V.84.-p.9238-9242.
17. Biasucci L., Vitelli A., Liuzzo G. et al. Elevated levels of interleukin- 6 in unstable angina // Circulation.- 1996.- 94.- p. 874-877.
18. Binns R.M., Licence S.T., Harrison A.A., Keelan E., Robinson M.,Haskard D. In vivo E-selectin upregulation correlates early with infiltration of PMN, later with PBL entry: MAвs block both // Am.J.Physiol.- Heart Circ. Physiol.- 1996.- 39.- p. H183- H193.
19. Blum A., Miller H. The Role of inflammation in atherosclerosis / /Israel J.Med.Sci.-1996.-V.32.-N.11.-p.1059-1065.
20. Bouma M.G., Vandenwildenberg F.A.J.M., Buurman W.A. Adenosine inhibits cytokine release and expression of adhesion molecults by activated human endothelial cells //Am.J.Physiol.- Cell.Physiol.-1996.-V.39.-N.2.-p.C522-C529.
21. Buerke M., Murohara T., Skurk C., Nuss C., Tomaselli K., Lefer A. Cardioprotective effect of insulin-like growth factor 1 in myocardial ischemia followed by reperfusion // Proc. Natl. Acad. Sci. USA.- 1995.- 92.- p. 8031-8035.
22. Bullough D., Magill M., Mullane K., Firestein G. Carbohydrate and CD18-dependent neutrophil adhesion to cardiac myocytes: effects of adenosine // Cardiovasc.Res.- 1996.- 32.-p.328-334.
23. Bult H. Nitric oxide and atherosclerosis: Possible implications for therapy //Molec. Med. Today.-1996.-V.2.-N.12.-p.510-518.
24. Burke S.E., Nelson R.A. Endothelin-receptor antagonist FR 139317 reduces infarct size in a rabbit model when given before, but not after, coronary artery occlusion //J.Cardiovasc.Pharmacol.-1997.- V.29.-N.1.-p.87-92.
25. Cannon C.P., McCabe C.H., Borzak S., Henry T.D. et al. Randomized trial of an oral platelеt glicoprotein IIb/IIIa antogonist, sibrafiban, in patients after an acute coronary syndrome // Circulation.-1998.-V.97.-p.340-349.
26. Carpenter K.L.H., Wilkins G.M., Fussell B. et al.Production of oxidised lipids during modification of low-density lipoprotein by macrophages or copper // Biochem J.-1994.-V.304.-p.625-633.
27. Cohen J.J. Overview: Mechanisms of apoptosis // Immunology today.-1993.-V.14.-N.3.-p.126-136.
28. Crea F., Biasucci L.M., Buffon A. et al. Role of inflammation in the pathogenesis of unstable coronary artery disease //Am.J.Cardiol.- 1997.-V.80.-N.4.-p.E10-E16.
29. Dabesh J., Muir J., Wong Y. et al. Risk factors for coronary heart disease and acute-phase proteins; a population-based study // Eur.Heart J.-1999.-V.20.-N.13.-p.954-960.
30. Danesh J., Collins R., Peto R. Cronic infections and coronary heart disease: is there a link? //Lancet.-1997.-V.350.-p.430-436.
31. Davies M.J., Richardsom P.D., Woolf N. et al. Risk of thrombosis in human atherosclerotic plaque: role of extracellular lipid, macrophage, and smooth muscle cell content //Br. Heart J.-1993.- V.69.-p.377-381.
32. Dayer J.M. Anti-cytokines. / Mononuclear Phagocytes, ed. by Ralph van Furth,1992.-p.375-380.
33. Deservi S., Mazzone A., Ricevuti G. et al. Clinical and angiographic correlates of leukocyte activation in unstable angina // J. Amer. College Cardiol.- 1995.- 26.- p.1146-1150.
34. Dinarello C.A. Controlling the production of interleukin-1 and tumor necrosis factor in disease // Nutrition.- 1995.- 11 Suppl.5.- p.695-697.
35. Ferrante A., Hauptmann B., Seckinger P., Dayer J.M. Ingibition of tumour necrosis factor alpha (TNFα)-induced neutrophil respiratory burst by a TNF inhibitor //Immunology.-1991.-V.72.-p.440-442.
36. Ferrara N. Vascular endothelial growth factor //Eur.J.of Cancer - 1996.-V.32A.-N.14.-p.2413-2422.
37. Ferrari R., Ceconi C., Curello S. et al. Protective effect of propionyl-L-carnitine against ischemia and reperfusion damage //Mol.Cell Biochem.-1989.-V.88.-p.161-168.
38. Ghezzi P., Dinarello C., Biamchi M., Rosamdich M., Repine J., White C.W. Hypoxia increases production of interleukin-1 and TNF by mononuclear cells // Cytokin.- 1991.- Vol.3.- p.189-194.
39. Gilmont R.R., Dardano A., Engle J.S. et al.TNF a- potentiates oxidant and reperfusion-induced endothelial cell injury //J.of Surg.Res.-1996.-V.G1.-N.1.-p.175-182.
40. Gotschlich E.C. C-reactive protein.A historical overview //Ann. New York Academy of sciences.-1992.-P.9-17.
41. Granger D.N., Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion (review) // J.Leukoc. Biol.- 1994.-V. 55.- p.662-675.
42. Gurfinkel E., Bozovich G., Beck E. et al. Treatment with the antibiotic roxithromycim in patients with acute non-Q-wave coronary syndromes; the final report of the ROXIS study //Eur.Heart J.-1999.-V.20.-N.2.-p.121-128.
43. Hardwick S.J., Hegyi L., Clare K. et al. Apoptosis in human monocyte-macrophages exposed to oxidised low-density lipoprotein //J.Pathol.-1996.-V.179.-p.294-302.
44. Harland W.A., Gilbert J.D., Brooks C.J.W. Lipids of human atheroma VIII. Oxidised derivatives of cholesteryl linoleate // Biochem Biophys Acta.-1973.-V.316.-p.378-385.
45. Hess M.L., Kukreja R. What are the prospects of antioxidants as a new therapeutic modality? //Dialogues in Cardiovasc.Med.-1998.- V.3.-N.1.-p.38-44.
46. Hisama N., Yamaguchi Y., Okajima K. et al. Anticoagulant pretreatment attenuates production of cytokine-induced neutrophil chemattractant following ischemia-reperfusion //Digest. Dis. Sci.- -1996.- 41.- p.1481-1486.
47. Homeister J.W., Satoh P., Kilgore K.S., Lucchesi B.R. Soluble complement receptor type 1 prevents human complement�mediated damage of the rabbit isolated heart //J.Immunol.-1993.- V.150.-p.1055-1064.
48. Horwitz L.D., Kaufman D., Kong Y. An antibody to leukocyte integrins attenuates coronary vascular injury due to ischemia and reperfusion in dogs //Am.J.Physiol.-1997.-V.272(2,pt 2).-p.H618-H624.
49. Ihling C., Gobel H.R., Lippoldt A. et al. Endothelin-1-like immunoreactivity in human atherosclerotic coronary tissue: A detailed analysis of the cellular distribution of endotelin-1 //J.of Pathology.-1996.-V179.-N3.-p.303-308.
50. Inoue T., Sakai Y., Morooka S., Hayashi T., Takayanagi K., Nakabatake Y. Expression of PMN leukocyte adhesion molecules and its clinical significanse in patients treated with percutaneous transluminal coronary angioplasty //J. Amer. College Cardiol.-1996.- - 28.- p.1127-1133.
51. Kang Y.H., Brummel S.E., LeeC.H. Differential effects of transforming growth factor-a 1 on lipopolisaccharide induction of endothelial adhesion molecules //Shock.-1993.-V.6.-N.2.-p.118- 125.
52. Kerttula T., Riutta A., Kaukinen S. et al. Noradrenaline and dopamine infusions modulate arachidonic acid cyclooxygenase and 5-lipoxygenase pathways ex vivo in man //Prostagland. Leuk.,Essent.Fatty.- 1995.- 53.- p.47-52.
53. Koifman B., Wollman Y., Bogomolny N. et al. Improvment of cardiac performance by intravenous infusion of L-arginine in patients with moderate congestive heart failure //J.Am Coll Cardiol.-1995.- V.26.-N.5.-p.1251-1256.
54. Kristensen S.D., Ravn H.B., Falk E. Insights into the pathophysiology of unstable coronary artery disease //Am.J.Cardiol.- 1997.-V.80.-N.4.-p.E5-E9.
55. Kumar M., Liu G.J., Floyd R.A., Grammas P. Anoxic injury of endothelial cells increases production of nitric oxide and hydroxyl radicals //Biochemical and Biophysical Research Communications.- 1996.-V.219.-N.2.-p.497-501.
56. Lefer D.J., Flynn D.M., Buda A.J. Combined inhibition of P-selectin and ICAM-1 reduces myocardial injury following ischemia and reperfusion //Amer. J. Physiol.- Heart Circul. Physiol.-1996.- 40(6).- p.H2421-H2429.
57. Lender R., Oldgren J., Egberg N. et al. The effect of a low molecular mass thrombin inhibitor, inogatran and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease //Eur.Heart J.-1999.-V.20.-N.7.-p.506-419.
58. Lepran I., Lefer A.M. Ischemic aggravating effects of platelet�activating factor in acute myocardial ischemia //Basic Res. Cardiol.- 1985.- 80.- Р.135-141.
59. Lerman A., Holmes D.R.Jr., Itagane H. et al. Local release of endothelin in human coronary arteris in response to balloon angioplasty //J.Am Coll Cardiol.-1994.- N23 (Special Issue):124A.
60. Libby P. Molecular bases of the acute coronary syndromes //Ibid.- 1995.-V92.-p.2844-2850.
61. Lincoff A.M., Korngold S. An overview of platelet GP IIb/IIIa receptor antagonists trials //Eur.HeartJ.-1999.-V.20(suppl E).-p.E18-E27.
62. Loetscher H., Pan Y.C.E., Lahm H.W. et al. Molecular cloning and expression of the human 55 kD tumor necrosis factor receptor // Cell.-1990.-V.61.-p.351-360.
63. Luizzo G., Biasucci L.M., Gallimore J.R. et al. The prognostic value of C-reactive protein and serumamyloid A protein in severe unstable angina //N.Engl.J.Med.-1994.-N.331.-p.417-424.
64. Luscher T.F., Noll G. Endothelium dysfunction in the coronary circulation //J. Cardiovasc. Pharmacol.-1994.-V.24(Suppl.3).-p.16-26.
65. Macdonald P.S., Read M.A., Dusting G.J. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin //Tromb. Res.-1988.-V.48.-p.437.
66. Madan M., Berkowitz S.D., Tcheng J.E. Glycoprotein IIb//III integrin blockads //Circulation. -1998.- V.98.-p.2629-2635.
67. Mantovani A., Bussolino F., Dejana E. Cytokine regulation of endothelial cell function // FASEB J.- 1992.- V.6.-p.2591-2599.
68. Marchant C.E., van der Veen C., Law N.S. et al. Oxidation of low�density lipoprotein by human monocyte-macrophages results in toxicity to the oxidising culture //Free Radic.Res.-1996.-V.24.-p.333-342.
69. Maseri A. Antibiotics for acute coronary syndromes: are we ready for magatrials? //Eur.Heart J.-1999.-V.20.-N.2.-p.89-93.
70. McKee P.A. Hemostasis and disorders of blood coagulation. In: The Metabolic Basis of Inherited Disease, 5th ed., Stanbury J.B. et al. (eds.), McGraw-Hill,1983.
71. Mehta J., Dinerman J., Mehta P. et al. Neutrophil function in ischemic heart disease // Circulation.- 1989.- 79.-p.549-556.
72. Milazzo V.J., Ferrante R.J., Sabido F., Silva M.B., Hobson R.W,., Dunan W. Time course of leukocyte adhesion to endothelium in ischemia-reperfusion //J.Surgical Res.- 1996.-V. 61.- p.139-142.
73. Missov E., Cambell A., Lebel B. Cytokine inhibitors in patients with heart failure and impaired functional capacity //Jpn.Circ.J.-1997.- V.61.-N.9.-P.749-754.
74. Miura T., Nelson D.P., Schermerhorn M.L. et al. Blockade of selectin�mediated leukocyte adhesion improves postischemic function in lamb hearts //Ann. Thoracic Surgery.- 1996.-V.62.-p. 1295-1300.
75. Momboli J.V., Vanhoutte P.M. Endothelial function after converting�enzyme inhibition //Medicographia.- 1996.-V.18.-N1.-P.35-40.
76. Nilson T., Cantera L., Adner M., Edvinsson L. Presence of contractile endothelin-A and dilatory endothelin-B receptors in human cerebral arteries //Neurosurgery.-1997.-V.40.-N.2.-p.346-351.
77. Orgaard O.S., Cantera L., Adner M., Edvinsson L. Endothelin-A and -B receptors in human coronary arteries and veins //Regulatory Peptides.-1996.-V.63.-N5.-p.149-156.
78. Pabla R., Buda A., Flynn D. et al. Nitric oxide attenuates neutrophil-mediated myocardial contractile dysfunction after ischemia and repetfusion //Circ Res.-1996.-V.78.-p.65-72.
79. Pradier O., Gerarad C., Delvaux A. et al. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide //Eur.J.Immunol.-1993.-V.23.-p.2700-2703.
80. Rapola J.M., Virtamo J., Huttunen J.K. Antioxidants and ischaemic heart disease //Lancet.-1997.-V.350(9078).-p.668.
81. Raschke P. Massoudy P., Becker B.F. Taurine protects the heart from neutrophil-induced reperfusion injury //Free Radical Biol. Med.- 1995.-V.19.- p.461-471.
82. Redmond E.M., Gahill P., Hodges R. et al., Regulation of endothelin receptors by nitric oxide in cultured rat vascular smooth muscle cells //J. Cell Physiol.-1996.-V.166.-N.3.-p.469-479.
83. Ross R. Endothelial dysfunction and atherosclerosis, ed by N.Simionescu and M.Simionescu.Plenum Press, New York,1992.-p.295-307.
84. Saijonmaa O., Ristimaki A., Fyhrquist F. Atrial natriuretic peptide, nitroglycerine,and nitroprusside reduce basal and stimulated endothelin production from cultured endothelial cells //Biochem Biophys Res Commun.-1990.- V.173.-p.514.
85. Saikku P., Mattila K. et al. Serological evidence of an association of novel Chlamydia, TWAR, with coronary heart disease and acute myocardial infarction //Lancet.-1998.-N.2.-p.983-986.
86. Sakurawi K., Yasuda F., Tozyo T. et al. Endothelin receptor antagonist triterpenoid,myriceric acid A, isolated from Myrica cerifera, and structure activity relationships of its derivatives // Chem.and Pharmacol.Bull.-1996.-V.44.-N.2.-p.343-351.
87. Samanen J. GPIIb/IIIa antagonists //Ann. Rep.Med.Chem.-1996.- V.31.- p.91-100.
88. Satre H., Holmvang L., Wager G.S. et al. Reduction of myocardial damage by prolonged treatment with subcutaneous low molecular weight heparin in unstable coronary artery disease //Eur.Heart J.- 1999.-V.20.-N.9.-p.645-653.
89. Schmidt F.E., Macdonald M.J., Murphy C.O., Brown W.M., Gott J.P., Guyton R.A. Leukocyte depletion of blood cardioplegia attenuates reperfusion injury //Ann. Thoracic Surgery.- 1996.- V.62. - p. 1691-1696.
90. Serrano C.V., Mikhail E.A., Wany P.H., Noble B. Kuppusamy P. Superoxide and hydrogen peroxide induce CD18-mediated adhesion in the postischemic heart //Biochim Biophys Acta.-1996.-V.316.-p.191-202.
91. Simpson P.J., Todd 3d,J.K., Mickelson J.C. et al. Sustained limitation of myocardial reperfusion injury by a monoclomal antibody that alters leukocyte function //Dialogues in Cardivasc.Med.-1998.-V.3.-N.1.-p.54.
92. Stenberg D. Oxidative modification of LDL and atherogenesis // Circulation.-1997.-N.95.-p.1062-1071.
93. Szabo C. The pathophysiological role of peroxynitrite in shock, inflammation and ischemia-reperfusion injury //Shock.-1996.-N.6.- p. 79-88.
94. The Investigators of the Study on propionyl-L-carnitine in heart failure. Study on prorionyl-L-carnitine in chronic heart failure // Eur.Heart J.-1999.-V.20.-N.1.-p.70-77.
95. Tonnessen T., Ilebekk A., Naess P., Christensen G. Inhibition of granulocyte-derived proteases reduces the increase in plasma endothelin associated with myocardial ischemia in the pig //Basic Res. Cardiol.- 1996.- V.91.- p.289-295.
96. Toopl E.J., Ferguson J.J., Wesman H.F. et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin b3 blocade with percutaneous coronary intervention: EPIC investigator Group: Evaluation of platelet IIb/IIIa ingimition for ptevention of ischemic complication //JAMA.-1997.-V.278.-p.479-484.
97. Verheggen P.W.H.M., de Maat M.P.M., Manger Cats V. et al. Inflammatory status as a main deterninant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function //Eur.Heart J.-1999.-V15.-N.9.-p.415-420.
98. Vitola J.V., Forman M.B., Holsinger J.P. et al. Role of endothelin in a rabbit model of acute myocardial infarction: effects of receptor antagonists //J.Cardiovasc Pharmacol.-1996.-V.28.-p.774-783.
99. Wallen N.H., Held C., Rehnqvist N., Hjemdahl P. Elevated serum intercellular adhesion molecule-1 and vascular adhesion molecule- 1 among patients with stable angina pectoris who suffer cardiovascular death or nonfatal myocardial infarction //Eur.Heart J.-1999.-V.20.-N.14.-p.1039-1044.
100. Wattiaux R., Jadot M., Warnierpirotte M.T., Wattiauxdeconinck S. Cationic lipids destabilize lysosomal membrane in vitro // FEBS Letters.-1997.-V.417.-N.2.-p. 199-202
101. Yang B.C., Chen L.Y., Saldeen T.G.P., Mehta J.L. Reperfusion injury in the endotoxin-treated rat heart: Reevaluation of the role of nitric oxide //British J.Pharmacol.-1997.-V.120.-N.2.-p.305-311.
102. Yuan X.M., Li W., Olsson A.G., Brunk U.T., The toxicity to macrophages of oxidized low-density lipoprotein is mediated through lysosomal damage.//Atherosclerosis.- 1997.-V.133.-N.2.-p.153-161.
103. Yudkin J.S. Coronary heart disease in diabetes mellitus: Three new risk factors and a unifying hypothesis //J.Internal Med.-1995.- V.238.-N.1.-p.21-30.
104. Zaugg C.E., Hornstein P.S., Zhu P.L. et al. Endothelin-1-induced release of thromboxane A2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts //Circulation.- 1996.-V.94.-N.4.-p.742-747.
105. Ziff M. Role of endothelium in chronic inflammation //Springer Semin Immunopathol.-1989.-V.1.-p.199-214.